Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quince Therapeutics SEC filings document a rare-disease biotechnology issuer with QNCX common stock registered for trading on the Nasdaq Global Select Market. The filings cover its AIDE drug/device technology, eDSP clinical and regulatory disclosures, operating risks, capital structure and public-company governance.
Recent filings include Form 8-K material-event reports on debt settlement, Nasdaq continued-listing matters, a reverse stock split, board composition and related governance changes. Proxy materials describe director elections, executive compensation, equity awards, board committees and shareholder voting matters, while reporting notices address annual-report timing and required disclosure preparation.
Quince Therapeutics (QNCX) filed a Form 4 disclosing that CEO, CMO and Director Dirk Thye increased his equity stake on 18 June 2025.
Thye acquired 150,944 common shares at $1.20 (Transaction Code A) and simultaneously received warrants for an additional 150,944 shares with the same $1.20 exercise price, expiring 18 June 2030. Following the transactions, his direct beneficial ownership rose to 994,885 common shares, an increase of roughly 15 %. The disclosed cash outlay for the common-share purchase is approximately $181 000; the warrants were priced at $0.125 each.
No shares were sold, and the filing does not indicate the use of a Rule 10b5-1 trading plan. These insider purchases may signal management confidence, though the dollar value is modest relative to typical market-moving thresholds.